Paper Details

  1. Home
  2. Paper Details

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.

Author: BrileyM, MontgomeryS A, ProstJ F, PuechA, SollesA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

Milnacipran, a serotonin-norepinephrine reuptake inhibitor, demonstrated similar efficacy to imipramine and superior efficacy to SSRIs in treating depression. It was well tolerated with fewer side effects compared to TCAs.
Paper Details　
Original Abstract of the Article :
Milnacipran (Ixel) is a new antidepressant with essentially equal potency for inhibiting the reuptake of both serotonin and noradrenaline, with no affinity for any neurotransmitter receptor studied. A review of the studies comparing milnacipran, placebo and active comparator antidepressants provides...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00004850-199703000-00005

データ提供：米国国立医学図書館（NLM）

A New Oasis in Depression Treatment: Milnacipran

Depression can feel like a vast and lonely desert, with many individuals seeking a path to relief. This research is like a guide, introducing milnacipran, a new serotonin and noradrenaline reuptake inhibitor, as a potential oasis in the treatment of depression. The authors provide an overview of milnacipran's antidepressant activity and clinical tolerability, comparing its effectiveness to other antidepressants, such as tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs).

Milnacipran Shows Promise as an Effective Antidepressant

This research is like a spring of hope in the desert of depression treatment. The authors found that milnacipran is an effective antidepressant, demonstrating efficacy in both severe and moderate depression. Furthermore, milnacipran appears to have a favorable tolerability profile compared to TCAs, with fewer cholinergic side effects.

A Potential New Option for Depression Treatment

This research is a reminder that the desert of depression treatment is constantly evolving. Milnacipran offers a potential new option for individuals seeking relief from depression, providing a potentially more effective and tolerable alternative to existing treatments. It's a testament to the ongoing search for new and innovative therapies to combat this debilitating condition.

Dr. Camel's Conclusion

This research provides a comprehensive overview of the antidepressant activity and clinical tolerability of milnacipran. The authors' findings suggest that milnacipran is an effective and well-tolerated antidepressant, potentially offering a new oasis of hope for individuals struggling with depression. This research is a valuable contribution to the ongoing effort to develop effective and tolerable treatments for this debilitating condition.
Date :
  1. Date Completed 1997-08-26
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

9219045

DOI: Digital Object Identifier

10.1097/00004850-199703000-00005

Related Literature

Article Analysis
・Effects of milnacipran
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.